global_id stringlengths 11 24 | source_dataset stringclasses 3
values | source_item_id stringlengths 1 6 | table_name stringclasses 3
values | question_id int64 1 9 | gene stringlengths 2 15 ⌀ | gene_name stringlengths 2 15 ⌀ | cancer_type stringclasses 32
values | cancer_type_acronym stringclasses 32
values | primary_site stringclasses 28
values | normal_tissue stringclasses 19
values | option_A stringlengths 2 64 | option_B stringlengths 2 64 | correct_option stringclasses 2
values | answer_text stringlengths 2 64 | pos_row_index int64 0 617k ⌀ | neg_row_index int64 1 618k ⌀ | pos_affected_cases_percent float64 2 86.1 ⌀ | neg_affected_cases_percent int64 0 0 ⌀ | pos_num_affected_cases int64 3 887 ⌀ | neg_num_affected_cases int64 0 0 ⌀ | pos_num_cases_total int64 125 5.55k ⌀ | neg_num_cases_total int64 125 5.55k ⌀ | messages listlengths 2 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
gene_expression:69750 | gene_expression | 69750 | gene_expression | 4 | ENSG00000054598 | FOXC1 | null | null | null | null | colon adenocarcinoma | kidney renal papillary cell carcinoma | B | kidney renal papillary cell carcinoma | 242,016 | 109,821 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is FOXC1 expression higher?\nA. colon adenocarcinoma\nB. kidney renal papillary cell carcinoma",
"role": "user"
},
{
"content": "B. kidney renal papillary cell carcinoma",
"role": "assistant"
}
] |
prognosis:8206 | prognosis | 8206 | prognosis | 1 | ENSG00000110042 | DTX4 | thyroid carcinoma | THCA | null | null | Yes | No | A | Yes | 269,219 | null | null | null | null | null | null | null | [
{
"content": "Question: Is DTX4 expression associated with a favorable prognosis in thyroid carcinoma?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:84636 | gene_expression | 84636 | gene_expression | 5 | null | null | kidney renal papillary cell carcinoma | KIRP | null | null | DMRTA2 | MRPS34 | B | MRPS34 | 239,767 | 245,209 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher expression in kidney renal papillary cell carcinoma cancer?\nA. DMRTA2\nB. MRPS34",
"role": "user"
},
{
"content": "B. MRPS34",
"role": "assistant"
}
] |
gene_expression:148055 | gene_expression | 148055 | gene_expression | 4 | ENSG00000140694 | PARN | null | null | null | null | uveal melanoma | ovarian serous cystadenocarcinoma | A | uveal melanoma | 602,392 | 356,887 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is PARN expression higher?\nA. uveal melanoma\nB. ovarian serous cystadenocarcinoma",
"role": "user"
},
{
"content": "A. uveal melanoma",
"role": "assistant"
}
] |
mutation_frequency:31566 | mutation_frequency | 31566 | mutation_frequency | 2 | OR51G2 | null | null | null | null | null | pancreas | lung | B | lung | 318,562 | 384,790 | 3.094141 | 0 | 47 | 0 | 1,519 | 484 | [
{
"content": "Question: In which cancer primary site is OR51G2 more frequently mutated?\nA. pancreas\nB. lung",
"role": "user"
},
{
"content": "B. lung",
"role": "assistant"
}
] |
gene_expression:181119 | gene_expression | 181119 | gene_expression | 6 | null | null | colon adenocarcinoma | COAD | null | Colon | COLGALT2 | C3orf38 | B | C3orf38 | 104,537 | 94,931 | null | null | null | null | null | null | [
{
"content": "Question: Which gene is higher in colon adenocarcinoma cancer vs Colon normal tissue?\nA. COLGALT2\nB. C3orf38",
"role": "user"
},
{
"content": "B. C3orf38",
"role": "assistant"
}
] |
mutation_frequency:23069 | mutation_frequency | 23069 | mutation_frequency | 2 | ATP6V1B1 | null | null | null | null | null | testis | colon | B | colon | 140,996 | 538,364 | 5.120482 | 0 | 34 | 0 | 664 | 142 | [
{
"content": "Question: In which cancer primary site is ATP6V1B1 more frequently mutated?\nA. testis\nB. colon",
"role": "user"
},
{
"content": "B. colon",
"role": "assistant"
}
] |
gene_expression:103364 | gene_expression | 103364 | gene_expression | 2 | ENSG00000127540 | UQCR11 | bladder urothelial carcinoma | BLCA | null | Bladder | Yes | No | A | Yes | 27,457 | null | null | null | null | null | null | null | [
{
"content": "Question: Is UQCR11 significantly lower on average in bladder urothelial carcinoma cancer than in Bladder normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:78897 | gene_expression | 78897 | gene_expression | 8 | null | null | pheochromocytoma and paraganglioma | PCPG | null | Adrenal Gland | ZIK1 | IL20RB | A | ZIK1 | 382,194 | 389,153 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in pheochromocytoma and paraganglioma cancer vs Adrenal Gland normal tissue?\nA. ZIK1\nB. IL20RB",
"role": "user"
},
{
"content": "A. ZIK1",
"role": "assistant"
}
] |
gene_expression:121626 | gene_expression | 121626 | gene_expression | 6 | null | null | cholangiocarcinoma | CHOL | null | Liver | NPAS3 | APOLTP | A | NPAS3 | 94,212 | 83,786 | null | null | null | null | null | null | [
{
"content": "Question: Which gene is higher in cholangiocarcinoma cancer vs Liver normal tissue?\nA. NPAS3\nB. APOLTP",
"role": "user"
},
{
"content": "A. NPAS3",
"role": "assistant"
}
] |
gene_expression:94772 | gene_expression | 94772 | gene_expression | 1 | ENSG00000130513 | GDF15 | pheochromocytoma and paraganglioma | PCPG | null | Adrenal Gland | Yes | No | A | Yes | 385,263 | null | null | null | null | null | null | null | [
{
"content": "Question: Is GDF15 significantly higher on average in pheochromocytoma and paraganglioma cancer than in Adrenal Gland normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:86312 | gene_expression | 86312 | gene_expression | 3 | ENSG00000078177 | N4BP2 | mesothelioma | MESO | null | Lung | Yes | No | B | No | null | 328,075 | null | null | null | null | null | null | [
{
"content": "Question: Is N4BP2 significantly more expressed on average in mesothelioma cancer (relative to any normal tissue)?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
mutation_frequency:14614 | mutation_frequency | 14614 | mutation_frequency | 2 | LRRC8A | null | null | null | null | null | adrenal gland | stomach | B | stomach | 518,005 | 10,257 | 3.276131 | 0 | 21 | 0 | 641 | 523 | [
{
"content": "Question: In which cancer primary site is LRRC8A more frequently mutated?\nA. adrenal gland\nB. stomach",
"role": "user"
},
{
"content": "B. stomach",
"role": "assistant"
}
] |
gene_expression:5139 | gene_expression | 5139 | gene_expression | 3 | ENSG00000171466 | ZNF562 | thymoma | THYM | null | null | Yes | No | A | Yes | 540,733 | null | null | null | null | null | null | null | [
{
"content": "Question: Is ZNF562 significantly more expressed on average in thymoma cancer (relative to any normal tissue)?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:111880 | gene_expression | 111880 | gene_expression | 2 | ENSG00000059377 | TBXAS1 | ovarian serous cystadenocarcinoma | OV | null | Ovary | Yes | No | B | No | null | 351,858 | null | null | null | null | null | null | [
{
"content": "Question: Is TBXAS1 significantly lower on average in ovarian serous cystadenocarcinoma cancer than in Ovary normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
gene_expression:184799 | gene_expression | 184799 | gene_expression | 6 | null | null | cholangiocarcinoma | CHOL | null | Liver | LHPP | MNX1 | B | MNX1 | 82,357 | 87,570 | null | null | null | null | null | null | [
{
"content": "Question: Which gene is higher in cholangiocarcinoma cancer vs Liver normal tissue?\nA. LHPP\nB. MNX1",
"role": "user"
},
{
"content": "B. MNX1",
"role": "assistant"
}
] |
gene_expression:125683 | gene_expression | 125683 | gene_expression | 6 | null | null | kidney renal papillary cell carcinoma | KIRP | null | Kidney | CHRNB2 | NPHS1 | A | CHRNB2 | 226,807 | 231,410 | null | null | null | null | null | null | [
{
"content": "Question: Which gene is higher in kidney renal papillary cell carcinoma cancer vs Kidney normal tissue?\nA. CHRNB2\nB. NPHS1",
"role": "user"
},
{
"content": "A. CHRNB2",
"role": "assistant"
}
] |
gene_expression:150091 | gene_expression | 150091 | gene_expression | 9 | ENSG00000212122 | TSSK1B | null | null | null | null | prostate adenocarcinoma | glioblastoma multiforme | B | glioblastoma multiforme | 154,655 | 400,160 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is the prevalence of TSSK1B higher?\nA. prostate adenocarcinoma\nB. glioblastoma multiforme",
"role": "user"
},
{
"content": "B. glioblastoma multiforme",
"role": "assistant"
}
] |
gene_expression:154634 | gene_expression | 154634 | gene_expression | 8 | null | null | kidney renal papillary cell carcinoma | KIRP | null | Kidney | CCDC112 | RAG2 | A | CCDC112 | 229,974 | 236,195 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in kidney renal papillary cell carcinoma cancer vs Kidney normal tissue?\nA. CCDC112\nB. RAG2",
"role": "user"
},
{
"content": "A. CCDC112",
"role": "assistant"
}
] |
mutation_frequency:44614 | mutation_frequency | 44614 | mutation_frequency | 1 | null | null | null | null | soft tissues | null | CENPJ | PRSS3 | A | CENPJ | 494,035 | 493,233 | 3.111111 | 0 | 7 | 0 | 225 | 225 | [
{
"content": "Question: Which of the following genes is more frequently mutated in soft tissues cancer?\nA. CENPJ\nB. PRSS3",
"role": "user"
},
{
"content": "A. CENPJ",
"role": "assistant"
}
] |
mutation_frequency:33088 | mutation_frequency | 33088 | mutation_frequency | 2 | SAR1B | null | null | null | null | null | soft tissues | corpus uteri | B | corpus uteri | 172,331 | 503,471 | 2.145215 | 0 | 13 | 0 | 606 | 225 | [
{
"content": "Question: In which cancer primary site is SAR1B more frequently mutated?\nA. soft tissues\nB. corpus uteri",
"role": "user"
},
{
"content": "B. corpus uteri",
"role": "assistant"
}
] |
gene_expression:153208 | gene_expression | 153208 | gene_expression | 9 | ENSG00000174473 | GALNTL6 | null | null | null | null | skin cutaneous melanoma | brain lower grade glioma | A | skin cutaneous melanoma | 462,972 | 255,237 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is the prevalence of GALNTL6 higher?\nA. skin cutaneous melanoma\nB. brain lower grade glioma",
"role": "user"
},
{
"content": "A. skin cutaneous melanoma",
"role": "assistant"
}
] |
gene_expression:167878 | gene_expression | 167878 | gene_expression | 2 | ENSG00000239779 | WBP1 | breast invasive carcinoma | BRCA | null | Breast | Yes | No | A | Yes | 55,734 | null | null | null | null | null | null | null | [
{
"content": "Question: Is WBP1 significantly lower on average in breast invasive carcinoma cancer than in Breast normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
prognosis:6711 | prognosis | 6711 | prognosis | 1 | ENSG00000167553 | TUBA1C | colon adenocarcinoma | COAD | null | null | Yes | No | A | Yes | 52,858 | null | null | null | null | null | null | null | [
{
"content": "Question: Is TUBA1C expression associated with a favorable prognosis in colon adenocarcinoma?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:143404 | gene_expression | 143404 | gene_expression | 5 | null | null | glioblastoma multiforme | GBM | null | null | MED28 | PRRX2 | A | MED28 | 157,221 | 152,547 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher expression in glioblastoma multiforme cancer?\nA. MED28\nB. PRRX2",
"role": "user"
},
{
"content": "A. MED28",
"role": "assistant"
}
] |
mutation_frequency:650 | mutation_frequency | 650 | mutation_frequency | 2 | ADAM12 | null | null | null | null | null | larynx | retroperitoneum/peritoneum | A | larynx | 266,333 | 442,941 | 3.030303 | 0 | 5 | 0 | 165 | 213 | [
{
"content": "Question: In which cancer primary site is ADAM12 more frequently mutated?\nA. larynx\nB. retroperitoneum/peritoneum",
"role": "user"
},
{
"content": "A. larynx",
"role": "assistant"
}
] |
mutation_frequency:74508 | mutation_frequency | 74508 | mutation_frequency | 2 | ZC2HC1A | null | null | null | null | null | kidney | corpus uteri | B | corpus uteri | 166,556 | 254,860 | 3.135314 | 0 | 19 | 0 | 606 | 1,647 | [
{
"content": "Question: In which cancer primary site is ZC2HC1A more frequently mutated?\nA. kidney\nB. corpus uteri",
"role": "user"
},
{
"content": "B. corpus uteri",
"role": "assistant"
}
] |
gene_expression:164289 | gene_expression | 164289 | gene_expression | 8 | null | null | glioblastoma multiforme | GBM | null | Brain | PRAMEF8 | EFR3A | A | PRAMEF8 | 165,394 | 166,415 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in glioblastoma multiforme cancer vs Brain normal tissue?\nA. PRAMEF8\nB. EFR3A",
"role": "user"
},
{
"content": "A. PRAMEF8",
"role": "assistant"
}
] |
gene_expression:152822 | gene_expression | 152822 | gene_expression | 8 | null | null | brain lower grade glioma | LGG | null | Brain | ATG2B | WASHC5 | B | WASHC5 | 257,385 | 251,632 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in brain lower grade glioma cancer vs Brain normal tissue?\nA. ATG2B\nB. WASHC5",
"role": "user"
},
{
"content": "B. WASHC5",
"role": "assistant"
}
] |
gene_expression:173426 | gene_expression | 173426 | gene_expression | 1 | ENSG00000146067 | FAM193B | skin cutaneous melanoma | SKCM | null | Skin | Yes | No | B | No | null | 464,798 | null | null | null | null | null | null | [
{
"content": "Question: Is FAM193B significantly higher on average in skin cutaneous melanoma cancer than in Skin normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
mutation_frequency:7209 | mutation_frequency | 7209 | mutation_frequency | 2 | POU2F2 | null | null | null | null | null | prostate | rectum | B | rectum | 422,725 | 400,649 | 2.962963 | 0 | 4 | 0 | 135 | 575 | [
{
"content": "Question: In which cancer primary site is POU2F2 more frequently mutated?\nA. prostate\nB. rectum",
"role": "user"
},
{
"content": "B. rectum",
"role": "assistant"
}
] |
gene_expression:154616 | gene_expression | 154616 | gene_expression | 9 | ENSG00000205456 | TP53TG3D | null | null | null | null | adrenocortical carcinoma | thyroid carcinoma | A | adrenocortical carcinoma | 12,410 | 522,305 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is the prevalence of TP53TG3D higher?\nA. adrenocortical carcinoma\nB. thyroid carcinoma",
"role": "user"
},
{
"content": "A. adrenocortical carcinoma",
"role": "assistant"
}
] |
gene_expression:82492 | gene_expression | 82492 | gene_expression | 1 | ENSG00000166793 | YPEL4 | ovarian serous cystadenocarcinoma | OV | null | Ovary | Yes | No | B | No | null | 345,031 | null | null | null | null | null | null | [
{
"content": "Question: Is YPEL4 significantly higher on average in ovarian serous cystadenocarcinoma cancer than in Ovary normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
mutation_frequency:38670 | mutation_frequency | 38670 | mutation_frequency | 2 | ATP13A1 | null | null | null | null | null | pancreas | skin | B | skin | 468,788 | 380,484 | 4.347826 | 0 | 9 | 0 | 207 | 484 | [
{
"content": "Question: In which cancer primary site is ATP13A1 more frequently mutated?\nA. pancreas\nB. skin",
"role": "user"
},
{
"content": "B. skin",
"role": "assistant"
}
] |
gene_expression:62115 | gene_expression | 62115 | gene_expression | 1 | ENSG00000100842 | EFS | kidney chromophobe | KICH | null | Kidney | Yes | No | B | No | null | 198,390 | null | null | null | null | null | null | [
{
"content": "Question: Is EFS significantly higher on average in kidney chromophobe cancer than in Kidney normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
gene_expression:67871 | gene_expression | 67871 | gene_expression | 7 | ENSG00000169223 | LMAN2 | null | null | null | null | Pancreas | Brain | A | Pancreas | 374,530 | 166,795 | null | null | null | null | null | null | [
{
"content": "Question: In which normal tissue is LMAN2 expression higher?\nA. Pancreas\nB. Brain",
"role": "user"
},
{
"content": "A. Pancreas",
"role": "assistant"
}
] |
mutation_frequency:46994 | mutation_frequency | 46994 | mutation_frequency | 1 | null | null | null | null | larynx | null | HNF1B | ZNF840P | A | HNF1B | 267,783 | 286,801 | 4.242424 | 0 | 7 | 0 | 165 | 165 | [
{
"content": "Question: Which of the following genes is more frequently mutated in larynx cancer?\nA. HNF1B\nB. ZNF840P",
"role": "user"
},
{
"content": "A. HNF1B",
"role": "assistant"
}
] |
gene_expression:51568 | gene_expression | 51568 | gene_expression | 9 | ENSG00000176928 | GCNT4 | null | null | null | null | brain lower grade glioma | cholangiocarcinoma | B | cholangiocarcinoma | 91,475 | 261,440 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is the prevalence of GCNT4 higher?\nA. brain lower grade glioma\nB. cholangiocarcinoma",
"role": "user"
},
{
"content": "B. cholangiocarcinoma",
"role": "assistant"
}
] |
gene_expression:113576 | gene_expression | 113576 | gene_expression | 5 | null | null | bladder urothelial carcinoma | BLCA | null | null | SYCE3 | SPART | B | SPART | 30,018 | 30,782 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher expression in bladder urothelial carcinoma cancer?\nA. SYCE3\nB. SPART",
"role": "user"
},
{
"content": "B. SPART",
"role": "assistant"
}
] |
gene_expression:119560 | gene_expression | 119560 | gene_expression | 1 | ENSG00000139914 | FITM1 | esophageal carcinoma | ESCA | null | Esophagus | Yes | No | B | No | null | 148,892 | null | null | null | null | null | null | [
{
"content": "Question: Is FITM1 significantly higher on average in esophageal carcinoma cancer than in Esophagus normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
gene_expression:14103 | gene_expression | 14103 | gene_expression | 3 | ENSG00000114455 | HHLA2 | colon adenocarcinoma | COAD | null | Colon | Yes | No | A | Yes | 96,012 | null | null | null | null | null | null | null | [
{
"content": "Question: Is HHLA2 significantly more expressed on average in colon adenocarcinoma cancer (relative to any normal tissue)?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
mutation_frequency:578 | mutation_frequency | 578 | mutation_frequency | 2 | PIM2 | null | null | null | null | null | rectum | corpus uteri | B | corpus uteri | 158,388 | 423,300 | 2.310231 | 0 | 14 | 0 | 606 | 135 | [
{
"content": "Question: In which cancer primary site is PIM2 more frequently mutated?\nA. rectum\nB. corpus uteri",
"role": "user"
},
{
"content": "B. corpus uteri",
"role": "assistant"
}
] |
gene_expression:181838 | gene_expression | 181838 | gene_expression | 8 | null | null | liver hepatocellular carcinoma | LIHC | null | Liver | RIC8A | TCF7L2 | A | RIC8A | 266,793 | 277,209 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in liver hepatocellular carcinoma cancer vs Liver normal tissue?\nA. RIC8A\nB. TCF7L2",
"role": "user"
},
{
"content": "A. RIC8A",
"role": "assistant"
}
] |
mutation_frequency:13071 | mutation_frequency | 13071 | mutation_frequency | 2 | SLC15A2 | null | null | null | null | null | bones/joints | corpus uteri | B | corpus uteri | 164,987 | 54,607 | 5.115512 | 0 | 31 | 0 | 606 | 125 | [
{
"content": "Question: In which cancer primary site is SLC15A2 more frequently mutated?\nA. bones/joints\nB. corpus uteri",
"role": "user"
},
{
"content": "B. corpus uteri",
"role": "assistant"
}
] |
mutation_frequency:64717 | mutation_frequency | 64717 | mutation_frequency | 2 | AOAH | null | null | null | null | null | testis | stomach | B | stomach | 513,941 | 536,017 | 2.652106 | 0 | 17 | 0 | 641 | 142 | [
{
"content": "Question: In which cancer primary site is AOAH more frequently mutated?\nA. testis\nB. stomach",
"role": "user"
},
{
"content": "B. stomach",
"role": "assistant"
}
] |
mutation_frequency:63076 | mutation_frequency | 63076 | mutation_frequency | 1 | null | null | null | null | lymph nodes | null | SNRPA1 | B3GALT1 | B | B3GALT1 | 345,641 | 343,061 | 5.072464 | 0 | 14 | 0 | 276 | 276 | [
{
"content": "Question: Which of the following genes is more frequently mutated in lymph nodes cancer?\nA. SNRPA1\nB. B3GALT1",
"role": "user"
},
{
"content": "B. B3GALT1",
"role": "assistant"
}
] |
gene_expression:90777 | gene_expression | 90777 | gene_expression | 8 | null | null | brain lower grade glioma | LGG | null | Brain | PATZ1 | ZSCAN22 | A | PATZ1 | 247,226 | 250,819 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in brain lower grade glioma cancer vs Brain normal tissue?\nA. PATZ1\nB. ZSCAN22",
"role": "user"
},
{
"content": "A. PATZ1",
"role": "assistant"
}
] |
gene_expression:176293 | gene_expression | 176293 | gene_expression | 6 | null | null | glioblastoma multiforme | GBM | null | Brain | ABCG1 | HOXD4 | B | HOXD4 | 166,773 | 151,854 | null | null | null | null | null | null | [
{
"content": "Question: Which gene is higher in glioblastoma multiforme cancer vs Brain normal tissue?\nA. ABCG1\nB. HOXD4",
"role": "user"
},
{
"content": "B. HOXD4",
"role": "assistant"
}
] |
gene_expression:118653 | gene_expression | 118653 | gene_expression | 2 | ENSG00000110245 | APOC3 | esophageal carcinoma | ESCA | null | Esophagus | Yes | No | B | No | null | 147,026 | null | null | null | null | null | null | [
{
"content": "Question: Is APOC3 significantly lower on average in esophageal carcinoma cancer than in Esophagus normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
gene_expression:64315 | gene_expression | 64315 | gene_expression | 5 | null | null | head and neck squamous cell carcinoma | HNSC | null | null | HHIP | PDLIM4 | B | PDLIM4 | 184,218 | 179,237 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher expression in head and neck squamous cell carcinoma cancer?\nA. HHIP\nB. PDLIM4",
"role": "user"
},
{
"content": "B. PDLIM4",
"role": "assistant"
}
] |
mutation_frequency:68888 | mutation_frequency | 68888 | mutation_frequency | 2 | CCT6A | null | null | null | null | null | prostate | uterus | B | uterus | 596,645 | 397,961 | 2.711864 | 0 | 8 | 0 | 295 | 575 | [
{
"content": "Question: In which cancer primary site is CCT6A more frequently mutated?\nA. prostate\nB. uterus",
"role": "user"
},
{
"content": "B. uterus",
"role": "assistant"
}
] |
gene_expression:113076 | gene_expression | 113076 | gene_expression | 4 | ENSG00000186160 | CYP4Z1 | null | null | null | null | uveal melanoma | cervical squamous cell carcinoma and endocervical adenocarcinoma | B | cervical squamous cell carcinoma and endocervical adenocarcinoma | 71,531 | 600,311 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is CYP4Z1 expression higher?\nA. uveal melanoma\nB. cervical squamous cell carcinoma and endocervical adenocarcinoma",
"role": "user"
},
{
"content": "B. cervical squamous cell carcinoma and endocervical adenocarcinoma",
"role": "assistant"
}
] |
gene_expression:129977 | gene_expression | 129977 | gene_expression | 4 | ENSG00000103184 | SEC14L5 | null | null | null | null | uveal melanoma | lymphoid neoplasm diffuse large b-cell lymphoma | A | uveal melanoma | 587,729 | 115,604 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is SEC14L5 expression higher?\nA. uveal melanoma\nB. lymphoid neoplasm diffuse large b-cell lymphoma",
"role": "user"
},
{
"content": "A. uveal melanoma",
"role": "assistant"
}
] |
gene_expression:146500 | gene_expression | 146500 | gene_expression | 1 | ENSG00000234906 | APOC2 | kidney chromophobe | KICH | null | Kidney | Yes | No | B | No | null | 206,371 | null | null | null | null | null | null | [
{
"content": "Question: Is APOC2 significantly higher on average in kidney chromophobe cancer than in Kidney normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
prognosis:8025 | prognosis | 8025 | prognosis | 2 | ENSG00000182628 | SKA2 | liver hepatocellular carcinoma | LIHC | null | null | Yes | No | A | Yes | 134,810 | null | null | null | null | null | null | null | [
{
"content": "Question: Is SKA2 expression associated with an unfavorable prognosis in liver hepatocellular carcinoma?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:69906 | gene_expression | 69906 | gene_expression | 3 | ENSG00000186810 | CXCR3 | lymphoid neoplasm diffuse large b-cell lymphoma | DLBC | null | null | Yes | No | A | Yes | 128,396 | null | null | null | null | null | null | null | [
{
"content": "Question: Is CXCR3 significantly more expressed on average in lymphoid neoplasm diffuse large b-cell lymphoma cancer (relative to any normal tissue)?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:78714 | gene_expression | 78714 | gene_expression | 9 | ENSG00000128944 | KNSTRN | null | null | null | null | cervical squamous cell carcinoma and endocervical adenocarcinoma | testicular germ cell tumors | A | cervical squamous cell carcinoma and endocervical adenocarcinoma | 67,505 | 501,860 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is the prevalence of KNSTRN higher?\nA. cervical squamous cell carcinoma and endocervical adenocarcinoma\nB. testicular germ cell tumors",
"role": "user"
},
{
"content": "A. cervical squamous cell carcinoma and endocervical adenocarcinoma",
"role": "a... |
prognosis:16715 | prognosis | 16715 | prognosis | 1 | ENSG00000141543 | EIF4A3 | kidney renal clear cell carcinoma | KIRC | null | null | Yes | No | A | Yes | 104,457 | null | null | null | null | null | null | null | [
{
"content": "Question: Is EIF4A3 expression associated with a favorable prognosis in kidney renal clear cell carcinoma?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
prognosis:5903 | prognosis | 5903 | prognosis | 1 | ENSG00000074370 | ATP2A3 | kidney renal clear cell carcinoma | KIRC | null | null | Yes | No | A | Yes | 99,666 | null | null | null | null | null | null | null | [
{
"content": "Question: Is ATP2A3 expression associated with a favorable prognosis in kidney renal clear cell carcinoma?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:82643 | gene_expression | 82643 | gene_expression | 8 | null | null | lung squamous cell carcinoma | LUSC | null | Lung | OR10C1 | SDK1 | B | SDK1 | 319,382 | 312,201 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in lung squamous cell carcinoma cancer vs Lung normal tissue?\nA. OR10C1\nB. SDK1",
"role": "user"
},
{
"content": "B. SDK1",
"role": "assistant"
}
] |
mutation_frequency:59362 | mutation_frequency | 59362 | mutation_frequency | 2 | TPRX2P | null | null | null | null | null | uterus | liver | A | uterus | 614,530 | 305,466 | 2.711864 | 0 | 8 | 0 | 295 | 443 | [
{
"content": "Question: In which cancer primary site is TPRX2P more frequently mutated?\nA. uterus\nB. liver",
"role": "user"
},
{
"content": "A. uterus",
"role": "assistant"
}
] |
gene_expression:18713 | gene_expression | 18713 | gene_expression | 9 | ENSG00000198734 | F5 | null | null | null | null | breast invasive carcinoma | prostate adenocarcinoma | B | prostate adenocarcinoma | 415,264 | 56,449 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is the prevalence of F5 higher?\nA. breast invasive carcinoma\nB. prostate adenocarcinoma",
"role": "user"
},
{
"content": "B. prostate adenocarcinoma",
"role": "assistant"
}
] |
gene_expression:121156 | gene_expression | 121156 | gene_expression | 7 | ENSG00000187676 | B3GLCT | null | null | null | null | Breast | Adrenal Gland | A | Breast | 43,164 | 5,394 | null | null | null | null | null | null | [
{
"content": "Question: In which normal tissue is B3GLCT expression higher?\nA. Breast\nB. Adrenal Gland",
"role": "user"
},
{
"content": "A. Breast",
"role": "assistant"
}
] |
mutation_frequency:30230 | mutation_frequency | 30230 | mutation_frequency | 1 | null | null | null | null | colon | null | AC008763.3 | ZNF483 | B | ZNF483 | 141,159 | 151,911 | 3.162651 | 0 | 21 | 0 | 664 | 664 | [
{
"content": "Question: Which of the following genes is more frequently mutated in colon cancer?\nA. AC008763.3\nB. ZNF483",
"role": "user"
},
{
"content": "B. ZNF483",
"role": "assistant"
}
] |
gene_expression:108906 | gene_expression | 108906 | gene_expression | 7 | ENSG00000125820 | NKX2-2 | null | null | null | null | Stomach | Cervix Uteri | A | Stomach | 487,190 | 71,720 | null | null | null | null | null | null | [
{
"content": "Question: In which normal tissue is NKX2-2 expression higher?\nA. Stomach\nB. Cervix Uteri",
"role": "user"
},
{
"content": "A. Stomach",
"role": "assistant"
}
] |
mutation_frequency:3453 | mutation_frequency | 3453 | mutation_frequency | 1 | null | null | null | null | tongue | null | OR4A19P | INPP4A | B | INPP4A | 575,149 | 595,573 | 3.205128 | 0 | 5 | 0 | 156 | 156 | [
{
"content": "Question: Which of the following genes is more frequently mutated in tongue cancer?\nA. OR4A19P\nB. INPP4A",
"role": "user"
},
{
"content": "B. INPP4A",
"role": "assistant"
}
] |
gene_expression:20217 | gene_expression | 20217 | gene_expression | 8 | null | null | sarcoma | SARC | null | Muscle | MYLK | SMPX | A | MYLK | 439,171 | 434,940 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in sarcoma cancer vs Muscle normal tissue?\nA. MYLK\nB. SMPX",
"role": "user"
},
{
"content": "A. MYLK",
"role": "assistant"
}
] |
gene_expression:80091 | gene_expression | 80091 | gene_expression | 7 | ENSG00000178597 | PSAPL1 | null | null | null | null | Stomach | Kidney | A | Stomach | 485,892 | 240,387 | null | null | null | null | null | null | [
{
"content": "Question: In which normal tissue is PSAPL1 expression higher?\nA. Stomach\nB. Kidney",
"role": "user"
},
{
"content": "A. Stomach",
"role": "assistant"
}
] |
mutation_frequency:41944 | mutation_frequency | 41944 | mutation_frequency | 2 | MAGI2 | null | null | null | null | null | heart/mediastinum/pleura | esophagus | B | esophagus | 177,734 | 199,810 | 5.394191 | 0 | 13 | 0 | 241 | 176 | [
{
"content": "Question: In which cancer primary site is MAGI2 more frequently mutated?\nA. heart/mediastinum/pleura\nB. esophagus",
"role": "user"
},
{
"content": "B. esophagus",
"role": "assistant"
}
] |
gene_expression:3243 | gene_expression | 3243 | gene_expression | 2 | ENSG00000169783 | LINGO1 | breast invasive carcinoma | BRCA | null | Breast | Yes | No | B | No | null | 54,105 | null | null | null | null | null | null | [
{
"content": "Question: Is LINGO1 significantly lower on average in breast invasive carcinoma cancer than in Breast normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
gene_expression:61407 | gene_expression | 61407 | gene_expression | 2 | ENSG00000187134 | AKR1C1 | stomach adenocarcinoma | STAD | null | Stomach | Yes | No | A | Yes | 482,418 | null | null | null | null | null | null | null | [
{
"content": "Question: Is AKR1C1 significantly lower on average in stomach adenocarcinoma cancer than in Stomach normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:182725 | gene_expression | 182725 | gene_expression | 2 | ENSG00000165495 | PKNOX2 | lung squamous cell carcinoma | LUSC | null | Lung | Yes | No | A | Yes | 307,864 | null | null | null | null | null | null | null | [
{
"content": "Question: Is PKNOX2 significantly lower on average in lung squamous cell carcinoma cancer than in Lung normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:168891 | gene_expression | 168891 | gene_expression | 1 | ENSG00000196126 | HLA-DRB1 | colon adenocarcinoma | COAD | null | Colon | Yes | No | A | Yes | 97,975 | null | null | null | null | null | null | null | [
{
"content": "Question: Is HLA-DRB1 significantly higher on average in colon adenocarcinoma cancer than in Colon normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
mutation_frequency:48788 | mutation_frequency | 48788 | mutation_frequency | 2 | SULT6B1 | null | null | null | null | null | skin | soft tissues | A | skin | 469,713 | 491,789 | 3.381643 | 0 | 7 | 0 | 207 | 225 | [
{
"content": "Question: In which cancer primary site is SULT6B1 more frequently mutated?\nA. skin\nB. soft tissues",
"role": "user"
},
{
"content": "A. skin",
"role": "assistant"
}
] |
mutation_frequency:71349 | mutation_frequency | 71349 | mutation_frequency | 2 | HDAC7 | null | null | null | null | null | esophagus | uterus | B | uterus | 597,283 | 177,839 | 5.084746 | 0 | 15 | 0 | 295 | 241 | [
{
"content": "Question: In which cancer primary site is HDAC7 more frequently mutated?\nA. esophagus\nB. uterus",
"role": "user"
},
{
"content": "B. uterus",
"role": "assistant"
}
] |
mutation_frequency:31449 | mutation_frequency | 31449 | mutation_frequency | 1 | null | null | null | null | lung | null | SLC5A11 | AC009093.8 | A | SLC5A11 | 316,570 | 330,054 | 3.094141 | 0 | 47 | 0 | 1,519 | 1,519 | [
{
"content": "Question: Which of the following genes is more frequently mutated in lung cancer?\nA. SLC5A11\nB. AC009093.8",
"role": "user"
},
{
"content": "A. SLC5A11",
"role": "assistant"
}
] |
mutation_frequency:18393 | mutation_frequency | 18393 | mutation_frequency | 2 | LUM | null | null | null | null | null | lung | bones/joints | A | lung | 312,077 | 47,165 | 2.172482 | 0 | 33 | 0 | 1,519 | 125 | [
{
"content": "Question: In which cancer primary site is LUM more frequently mutated?\nA. lung\nB. bones/joints",
"role": "user"
},
{
"content": "A. lung",
"role": "assistant"
}
] |
mutation_frequency:39947 | mutation_frequency | 39947 | mutation_frequency | 1 | null | null | null | null | rectum | null | ZNF517 | C1GALT1 | A | ZNF517 | 427,260 | 431,497 | 3.703704 | 0 | 5 | 0 | 135 | 135 | [
{
"content": "Question: Which of the following genes is more frequently mutated in rectum cancer?\nA. ZNF517\nB. C1GALT1",
"role": "user"
},
{
"content": "A. ZNF517",
"role": "assistant"
}
] |
gene_expression:178473 | gene_expression | 178473 | gene_expression | 2 | ENSG00000186788 | SPATA31D3 | testicular germ cell tumors | TGCT | null | Testis | Yes | No | A | Yes | 493,805 | null | null | null | null | null | null | null | [
{
"content": "Question: Is SPATA31D3 significantly lower on average in testicular germ cell tumors cancer than in Testis normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
prognosis:14708 | prognosis | 14708 | prognosis | 2 | ENSG00000196724 | ZNF418 | kidney renal papillary cell carcinoma | KIRP | null | null | Yes | No | B | No | null | 123,405 | null | null | null | null | null | null | [
{
"content": "Question: Is ZNF418 expression associated with an unfavorable prognosis in kidney renal papillary cell carcinoma?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
gene_expression:94172 | gene_expression | 94172 | gene_expression | 7 | ENSG00000142864 | SERBP1 | null | null | null | null | Testis | Muscle | B | Muscle | 445,025 | 501,680 | null | null | null | null | null | null | [
{
"content": "Question: In which normal tissue is SERBP1 expression higher?\nA. Testis\nB. Muscle",
"role": "user"
},
{
"content": "B. Muscle",
"role": "assistant"
}
] |
mutation_frequency:55530 | mutation_frequency | 55530 | mutation_frequency | 1 | null | null | null | null | larynx | null | SCN1A | WDR20 | A | SCN1A | 272,517 | 268,273 | 11.515152 | 0 | 19 | 0 | 165 | 165 | [
{
"content": "Question: Which of the following genes is more frequently mutated in larynx cancer?\nA. SCN1A\nB. WDR20",
"role": "user"
},
{
"content": "A. SCN1A",
"role": "assistant"
}
] |
prognosis:1964 | prognosis | 1964 | prognosis | 1 | ENSG00000188687 | SLC4A5 | lung adenocarcinoma | LUAD | null | null | Yes | No | A | Yes | 149,387 | null | null | null | null | null | null | null | [
{
"content": "Question: Is SLC4A5 expression associated with a favorable prognosis in lung adenocarcinoma?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:111067 | gene_expression | 111067 | gene_expression | 1 | ENSG00000166451 | CENPN | pheochromocytoma and paraganglioma | PCPG | null | Adrenal Gland | Yes | No | B | No | null | 385,401 | null | null | null | null | null | null | [
{
"content": "Question: Is CENPN significantly higher on average in pheochromocytoma and paraganglioma cancer than in Adrenal Gland normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
gene_expression:5871 | gene_expression | 5871 | gene_expression | 1 | ENSG00000197601 | FAR1 | kidney chromophobe | KICH | null | Kidney | Yes | No | A | Yes | 206,161 | null | null | null | null | null | null | null | [
{
"content": "Question: Is FAR1 significantly higher on average in kidney chromophobe cancer than in Kidney normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:40026 | gene_expression | 40026 | gene_expression | 2 | ENSG00000167548 | KMT2D | sarcoma | SARC | null | Muscle | Yes | No | A | Yes | 445,338 | null | null | null | null | null | null | null | [
{
"content": "Question: Is KMT2D significantly lower on average in sarcoma cancer than in Muscle normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
prognosis:2286 | prognosis | 2286 | prognosis | 2 | ENSG00000136261 | BZW2 | kidney chromophobe | KICH | null | null | Yes | No | A | Yes | 91,128 | null | null | null | null | null | null | null | [
{
"content": "Question: Is BZW2 expression associated with an unfavorable prognosis in kidney chromophobe?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:60939 | gene_expression | 60939 | gene_expression | 8 | null | null | liver hepatocellular carcinoma | LIHC | null | Liver | CENPW | TRMT10B | A | CENPW | 274,306 | 281,758 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in liver hepatocellular carcinoma cancer vs Liver normal tissue?\nA. CENPW\nB. TRMT10B",
"role": "user"
},
{
"content": "A. CENPW",
"role": "assistant"
}
] |
gene_expression:98705 | gene_expression | 98705 | gene_expression | 7 | ENSG00000152977 | ZIC1 | null | null | null | null | Cervix Uteri | Muscle | B | Muscle | 437,956 | 60,256 | null | null | null | null | null | null | [
{
"content": "Question: In which normal tissue is ZIC1 expression higher?\nA. Cervix Uteri\nB. Muscle",
"role": "user"
},
{
"content": "B. Muscle",
"role": "assistant"
}
] |
gene_expression:114449 | gene_expression | 114449 | gene_expression | 8 | null | null | kidney chromophobe | KICH | null | Kidney | DDX17 | NAT8L | B | NAT8L | 192,212 | 201,039 | null | null | null | null | null | null | [
{
"content": "Question: Which gene has a higher prevalence in kidney chromophobe cancer vs Kidney normal tissue?\nA. DDX17\nB. NAT8L",
"role": "user"
},
{
"content": "B. NAT8L",
"role": "assistant"
}
] |
mutation_frequency:56318 | mutation_frequency | 56318 | mutation_frequency | 1 | null | null | null | null | bladder | null | USP25 | TMEM265 | A | USP25 | 30,492 | 42,254 | 2.777778 | 0 | 12 | 0 | 432 | 432 | [
{
"content": "Question: Which of the following genes is more frequently mutated in bladder cancer?\nA. USP25\nB. TMEM265",
"role": "user"
},
{
"content": "A. USP25",
"role": "assistant"
}
] |
gene_expression:95147 | gene_expression | 95147 | gene_expression | 2 | ENSG00000019102 | VSIG2 | liver hepatocellular carcinoma | LIHC | null | Liver | Yes | No | B | No | null | 268,700 | null | null | null | null | null | null | [
{
"content": "Question: Is VSIG2 significantly lower on average in liver hepatocellular carcinoma cancer than in Liver normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
mutation_frequency:71529 | mutation_frequency | 71529 | mutation_frequency | 1 | null | null | null | null | rectum | null | DCLRE1CP1 | PRDM9 | B | PRDM9 | 419,700 | 439,368 | 5.925926 | 0 | 8 | 0 | 135 | 135 | [
{
"content": "Question: Which of the following genes is more frequently mutated in rectum cancer?\nA. DCLRE1CP1\nB. PRDM9",
"role": "user"
},
{
"content": "B. PRDM9",
"role": "assistant"
}
] |
mutation_frequency:23880 | mutation_frequency | 23880 | mutation_frequency | 2 | ATP9B | null | null | null | null | null | stomach | bones/joints | A | stomach | 514,768 | 51,172 | 2.808112 | 0 | 18 | 0 | 641 | 125 | [
{
"content": "Question: In which cancer primary site is ATP9B more frequently mutated?\nA. stomach\nB. bones/joints",
"role": "user"
},
{
"content": "A. stomach",
"role": "assistant"
}
] |
gene_expression:132781 | gene_expression | 132781 | gene_expression | 6 | null | null | pheochromocytoma and paraganglioma | PCPG | null | Adrenal Gland | EGR1 | COL11A1 | A | EGR1 | 391,820 | 395,242 | null | null | null | null | null | null | [
{
"content": "Question: Which gene is higher in pheochromocytoma and paraganglioma cancer vs Adrenal Gland normal tissue?\nA. EGR1\nB. COL11A1",
"role": "user"
},
{
"content": "A. EGR1",
"role": "assistant"
}
] |
gene_expression:135395 | gene_expression | 135395 | gene_expression | 1 | ENSG00000134183 | GNAT2 | bladder urothelial carcinoma | BLCA | null | Bladder | Yes | No | A | Yes | 33,350 | null | null | null | null | null | null | null | [
{
"content": "Question: Is GNAT2 significantly higher on average in bladder urothelial carcinoma cancer than in Bladder normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "A. Yes",
"role": "assistant"
}
] |
gene_expression:25531 | gene_expression | 25531 | gene_expression | 4 | ENSG00000117148 | ACTL8 | null | null | null | null | thyroid carcinoma | colon adenocarcinoma | B | colon adenocarcinoma | 105,610 | 521,080 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is ACTL8 expression higher?\nA. thyroid carcinoma\nB. colon adenocarcinoma",
"role": "user"
},
{
"content": "B. colon adenocarcinoma",
"role": "assistant"
}
] |
gene_expression:109863 | gene_expression | 109863 | gene_expression | 9 | ENSG00000083817 | ZNF416 | null | null | null | null | kidney chromophobe | esophageal carcinoma | A | kidney chromophobe | 189,625 | 132,970 | null | null | null | null | null | null | [
{
"content": "Question: In which cancer type is the prevalence of ZNF416 higher?\nA. kidney chromophobe\nB. esophageal carcinoma",
"role": "user"
},
{
"content": "A. kidney chromophobe",
"role": "assistant"
}
] |
gene_expression:17966 | gene_expression | 17966 | gene_expression | 2 | ENSG00000112494 | UNC93A | kidney renal papillary cell carcinoma | KIRP | null | Kidney | Yes | No | B | No | null | 228,151 | null | null | null | null | null | null | [
{
"content": "Question: Is UNC93A significantly lower on average in kidney renal papillary cell carcinoma cancer than in Kidney normal tissue?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
gene_expression:80933 | gene_expression | 80933 | gene_expression | 3 | ENSG00000234776 | FREY1 | ovarian serous cystadenocarcinoma | OV | null | Ovary | Yes | No | B | No | null | 350,626 | null | null | null | null | null | null | [
{
"content": "Question: Is FREY1 significantly more expressed on average in ovarian serous cystadenocarcinoma cancer (relative to any normal tissue)?\nA. Yes\nB. No",
"role": "user"
},
{
"content": "B. No",
"role": "assistant"
}
] |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 6